DK0721777T3 - Anvendelse af tomoxetin til behandling af uopmærksomheds/hyperaktivitetssygdom - Google Patents

Anvendelse af tomoxetin til behandling af uopmærksomheds/hyperaktivitetssygdom

Info

Publication number
DK0721777T3
DK0721777T3 DK96300157T DK96300157T DK0721777T3 DK 0721777 T3 DK0721777 T3 DK 0721777T3 DK 96300157 T DK96300157 T DK 96300157T DK 96300157 T DK96300157 T DK 96300157T DK 0721777 T3 DK0721777 T3 DK 0721777T3
Authority
DK
Denmark
Prior art keywords
tomoxetine
hyperactivity disorder
treat
inattention
treat inattention
Prior art date
Application number
DK96300157T
Other languages
Danish (da)
English (en)
Inventor
John Harrison Heiligenstein
Gary Dennis Tollefson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23463572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0721777(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0721777T3 publication Critical patent/DK0721777T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
DK96300157T 1995-01-11 1996-01-09 Anvendelse af tomoxetin til behandling af uopmærksomheds/hyperaktivitetssygdom DK0721777T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/371,341 US5658590A (en) 1995-01-11 1995-01-11 Treatment of attention-deficit/hyperactivity disorder

Publications (1)

Publication Number Publication Date
DK0721777T3 true DK0721777T3 (da) 2002-10-07

Family

ID=23463572

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96300157T DK0721777T3 (da) 1995-01-11 1996-01-09 Anvendelse af tomoxetin til behandling af uopmærksomheds/hyperaktivitetssygdom

Country Status (28)

Country Link
US (1) US5658590A (fr)
EP (1) EP0721777B1 (fr)
JP (2) JPH10512262A (fr)
KR (1) KR19980701276A (fr)
CN (2) CN1781480A (fr)
AT (1) ATE222757T1 (fr)
AU (1) AU688665B2 (fr)
BR (1) BR9606903A (fr)
CA (1) CA2209735C (fr)
CZ (1) CZ292226B6 (fr)
DE (2) DE122005000011I2 (fr)
DK (1) DK0721777T3 (fr)
ES (1) ES2181845T3 (fr)
FI (1) FI119354B (fr)
FR (1) FR10C0041I2 (fr)
HU (1) HU227306B1 (fr)
LU (1) LU91238I2 (fr)
NL (1) NL300180I2 (fr)
NO (1) NO317027B1 (fr)
NZ (1) NZ301500A (fr)
PL (1) PL187573B1 (fr)
PT (1) PT721777E (fr)
RO (1) RO118374B1 (fr)
RU (1) RU2163802C2 (fr)
SI (1) SI0721777T1 (fr)
TR (1) TR199700627T1 (fr)
UA (1) UA43385C2 (fr)
WO (1) WO1996021430A1 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
GB9613243D0 (en) * 1996-06-25 1996-08-28 Britannia Pharmaceuticals Ltd Attention deficit hyperactive disorder
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
AU9214498A (en) * 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
US5902797A (en) * 1997-11-10 1999-05-11 Beth Israel Deaconess Medical Center Nutritional supplement for use in the treatment of attention deficit
ES2244189T3 (es) * 1998-04-09 2005-12-01 PHARMACIA & UPJOHN COMPANY LLC Uso de reboxetina para el tratamiento de trastornos neuropsiquiatricos.
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
PT2055313E (pt) * 1998-11-09 2015-08-25 Biogen Idec Inc Tratamento de malignidades hematológicas associadas a células tumorais em circulação utilizando anticorpo quimérico anti-cd20
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6400978B1 (en) 1999-10-29 2002-06-04 The Mclean Hospital Corporation Method and apparatus for detecting mental disorders
US6898455B2 (en) * 1999-10-29 2005-05-24 The Mclean Hospital Corporation Method for providing optimal drug dosage
IL150479A0 (en) * 2000-03-07 2002-12-01 Lilly Co Eli Treatment of psoriasis
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
US20050009925A1 (en) * 2001-12-11 2005-01-13 Bymaster Franklin Porter Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
ES2315525T3 (es) 2002-08-23 2009-04-01 Eli Lilly And Company Derivados de 2-(feniltiometil)-morfolina para uso como inhibidores selectivos de la recaptacion de norepinefrina.
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2004103356A2 (fr) * 2003-05-15 2004-12-02 Eli Lilly And Company Traitement du dysfonctionnement emotionnel
WO2005011583A2 (fr) * 2003-07-28 2005-02-10 Leslie Joe Dunaway Traitement de la rhinite allergique et de l'asthme
EP1660064A2 (fr) * 2003-08-27 2006-05-31 Eli Lilly And Company Traitement de difficultes d'apprentissage et de troubles de la motricite faisant appel a des inhibiteurs de la recapture de la noradrenaline
CA2536161A1 (fr) * 2003-08-27 2005-03-10 Eli Lilly And Company Traitement des troubles profonds du developpement au moyen d'inhibiteurs de la recapture de la norepinephrine
ES2390879T3 (es) * 2003-12-31 2012-11-19 Actavis Group Ptc Ehf. Formulaciones de atomoxetina
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
JP2008500325A (ja) * 2004-05-27 2008-01-10 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 注意欠陥多動性障害の治療用の組合せ
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
CA2561866A1 (fr) * 2004-06-28 2006-01-12 Teva Pharmaceutical Fine Chemicals S.R.L. Resolution optique et recyclage de la tomoxetine
CN1976894A (zh) * 2004-07-22 2007-06-06 特瓦药物精化学品股份有限公司 阿托莫西汀盐酸盐的多形体
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
WO2006047493A2 (fr) 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Compositions pharmaceutiques a saveur masquee avec substances porogenes gastrosolubles
JP2008501721A (ja) * 2005-04-05 2008-01-24 テバ ファーマシューティカル ファイン ケミカルズ ソチエタ レスポンサビリタ リミテ 安定性アトモキセチン塩酸塩、その調製方法及びその安定性の分析的調節
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
WO2007062119A1 (fr) * 2005-11-23 2007-05-31 Auspex Pharmaceuticals, Inc. Aryloxypropylamines substituées possédant une activité sérotoninergique et/ou norépinephrinergique
JP2009518337A (ja) 2005-12-07 2009-05-07 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ 皮質カテコールアミン作動性神経伝達のモジュレーターとしての二置換フェニルピペリジン
US20080020387A1 (en) * 2006-03-31 2008-01-24 Lawrence Donald G Biomarker-optimized adhd treatment
US20080146675A1 (en) * 2006-04-05 2008-06-19 Eugenio Castelli Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
US20080031932A1 (en) * 2006-08-04 2008-02-07 Watson Laboratories, Inc. Transdermal atomoxetine formulations and associated methods
US20080145318A1 (en) * 2006-12-13 2008-06-19 Midha Kamal K Atomoxetine formulations and associated methods
WO2008122019A1 (fr) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Amélioration de la tolérabilité de la mirtazapine et de la réboxétine par leur utilisation en combinaison
WO2010028207A2 (fr) * 2008-09-05 2010-03-11 Supernus Pharmaceuticals, Inc. Procédé de traitement de trouble déficitaire de l’attention avec hyperactivité (adhd)
RU2395313C2 (ru) * 2008-10-15 2010-07-27 Татьяна Прохоровна Тетерина Способ коррекции синдрома дефицита внимания и гиперактивности
CN108159019A (zh) 2009-12-02 2018-06-15 阿黛尔药物有限公司 非索非那定微胶囊及含有非索非那定微胶囊的组合物
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
ES2883589T3 (es) 2011-03-23 2021-12-09 Ironshore Pharmaceuticals & Dev Inc Procedimientos y composiciones para el tratamiento del trastorno de déficit de atención
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
MX356727B (es) 2012-02-08 2018-06-12 Supernus Pharmaceuticals Inc Formulaciones de liberacion modificada de viloxacina.
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
EP2838510B1 (fr) 2013-11-08 2016-09-21 Eli Lilly and Company Solution d'atomoxétine
CA3018328A1 (fr) 2014-10-31 2016-04-30 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457121A (en) * 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine

Also Published As

Publication number Publication date
CZ214597A3 (cs) 1998-01-14
AU688665B2 (en) 1998-03-12
WO1996021430A1 (fr) 1996-07-18
NL300180I1 (nl) 2005-05-02
RO118374B1 (ro) 2003-05-30
FI972922A0 (fi) 1997-07-09
HUP9801283A2 (hu) 1999-06-28
JP2005325139A (ja) 2005-11-24
FR10C0041I1 (fr) 2010-10-15
SI0721777T1 (en) 2003-02-28
NO317027B1 (no) 2004-07-26
NO973170D0 (no) 1997-07-08
BR9606903A (pt) 1997-10-21
FI972922A (fi) 1997-07-09
EP0721777A3 (fr) 1997-03-05
UA43385C2 (uk) 2001-12-17
NZ301500A (en) 2000-07-28
LU91238I2 (fr) 2006-07-03
DE122005000011I1 (de) 2005-06-23
HUP9801283A3 (en) 1999-09-28
NO973170L (no) 1997-09-02
JPH10512262A (ja) 1998-11-24
MX9705117A (es) 1997-10-31
FI119354B (fi) 2008-10-31
US5658590A (en) 1997-08-19
ATE222757T1 (de) 2002-09-15
PL321273A1 (en) 1997-11-24
PT721777E (pt) 2002-11-29
RU2163802C2 (ru) 2001-03-10
PL187573B1 (pl) 2004-08-31
DE69623141D1 (de) 2002-10-02
EP0721777A2 (fr) 1996-07-17
DE122005000011I2 (de) 2006-02-09
TR199700627T1 (xx) 1998-01-21
CA2209735A1 (fr) 1996-07-18
CN1781480A (zh) 2006-06-07
HU227306B1 (en) 2011-03-28
EP0721777B1 (fr) 2002-08-28
AU4693896A (en) 1996-07-31
CA2209735C (fr) 2002-10-01
FR10C0041I2 (fr) 2011-04-29
NL300180I2 (nl) 2005-08-01
CZ292226B6 (cs) 2003-08-13
ES2181845T3 (es) 2003-03-01
DE69623141T2 (de) 2003-04-24
KR19980701276A (ko) 1998-05-15
CN1168095A (zh) 1997-12-17

Similar Documents

Publication Publication Date Title
DK0721777T3 (da) Anvendelse af tomoxetin til behandling af uopmærksomheds/hyperaktivitetssygdom
ES2054747T3 (es) Nuevos antidepresivos.
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
DK0700380T3 (da) N-Alkylthiopolyaminderivater som radioprotektive midler
MX9800589A (es) Tratamiento de desorden de la falta de atencion/hiperactividad.
BR0213581A (pt) Uso de um inibidor de recaptação de norepinefrina seletivo
DK0914605T3 (da) Molekylemodel for VLA-4-inhibitorer
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
DK1019347T3 (da) Fremgangsmåde til syntesen af taxaner
BR9711960A (pt) Verapamil como um medicamento para o tratamento de angina
DE69616582D1 (de) Stabilisierung von nitrilen
ES2156868T3 (es) Compuestos de arilalcoxifenoxi-imidazolina.
DK0673902T3 (da) Middel til behandling af bioaffald
ES2151615T3 (es) Procedimiento para la obtencion de pirazoles.
MX9300660A (es) Sintesis asimetrica.
ES2141044B1 (es) Terapia con oxibutinina.
ES2074194T3 (es) Procedimiento para la preparacion de 2-cloro-1,7-dihidropurin-6-ona y procedimiento para su purificacion.